MedPath

Duragen® Secure Post Marketing Clinical Follow-up (PMCF)

Completed
Conditions
Surgery
Dura Mater Nick Cut or Tear
Registration Number
NCT02225080
Lead Sponsor
Integra LifeSciences Corporation
Brief Summary

The purpose of this study is to gather information about post-market performance of DuraGen Secure.The aim of this post market clinical follow-up (PMCF) is to obtain post market clinical data to evaluate the presence of unintended residual risks associated with the use of DuraGen Secure that were not anticipated or identified in the animal studies, bench studies or clinical evaluation report.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Patient who have undergone a neurosurgical procedure where DuraGen® Secure has been implanted
Exclusion Criteria
  • Patient who does not agree to allow collection of his/her medical data

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patient's OutcomeDay 30

Patient outcome from the procedure (recovered without sequelae, ongoing with medical intervention, ongoing with surgical intervention, deceased, other)

Secondary Outcome Measures
NameTimeMethod
Occurence of Adverse EventBetween days 15-30

Adverse event that occured between days 15-30 post-operatively

Trial Locations

Locations (5)

Hopital Lariboisière

🇫🇷

Paris, France

die Charité - Universitätsmedizin Berlin

🇩🇪

Berlin, Germany

National Hospital for Neurology and Neurosurgery

🇬🇧

London, United Kingdom

Hospital Universitario La Fe

🇪🇸

Valencia, Spain

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath